MetaCap

Aclarion (ACON) vs Sera Prognostics (SERA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Sera Prognostics is the larger company by market cap ($72.0 million vs $3.5 million), about 20.4 times the size, while Aclarion is growing revenue faster (+65.6% vs +5.2%). Aclarion converts more of its revenue into profit, with a net margin of -9551.9% versus -39417.3%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ACON-47.98%SERA-12.56%
+8%-21%-51%
Oct 7, 20261 yearNov 20, 2026
ACON-47.76%SERA-11.27%
+10%-20%-51%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ACON versus SERA key metrics
MetricACONSERA
Share price$1.22$1.81
Market cap$3.52M$71.98M
1-day change-13.92%-4.23%
YTD return—-38.64%
1-year return—-43.96%
5-year return—-83.55%
EPS (TTM)$-5.01$-0.67
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$75.73K$81.00K
Revenue growth (YoY)+65.62%+5.19%
Net income (latest FY)$-7.23M$-31.93M
Gross margin9.02%-102.47%
Operating margin-9312.55%-45066.67%
Net margin-9551.87%-39417.28%
52-week high$9.36$3.85
52-week low$1.22$1.56
Distance from 52-week high-86.94%-52.99%
Analyst consensusstrong_buynone
Avg. price target upside+524.18%+203.87%
Average volume34.73K27.84K
Shares outstanding2.88M38.80M
Employees1071
SectorHealth CareHealth Care
IndustryMedical SpecialitiesMedical Specialities

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Sera Prognostics is about 20.4 times larger than Aclarion by market value ($71.98M vs $3.52M).
  • Aclarion is more profitable, keeping -9551.9 cents of every revenue dollar as net income versus -39417.3 cents for Sera Prognostics.
  • Aclarion grew revenue faster in its latest fiscal year (+65.62% vs +5.19%).

About Aclarion

ACON stock →

Aclarion, Inc. operates as a healthcare technology company in the United States.

Health Care · Medical Specialities · 10 employees

About Sera Prognostics

SERA stock →

Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation.

Health Care · Medical Specialities · 71 employees

ACON vs SERA FAQ

Which is bigger, Aclarion or Sera Prognostics?

Sera Prognostics (SERA) is larger, with a market capitalization of $71.98M compared with $3.52M for Aclarion (ACON).

Are Aclarion and Sera Prognostics in the same industry?

Yes. Both are classified in the Medical Specialities industry within the Health Care sector.

More comparisons